Drugs /

al101

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable, small-molecule gamma secretase (GS) and pan-Notch inhibitor, with potential antineoplastic activity. Upon administration, GS/pan-Notch inhibitor BMS-906024 binds to GS and blocks activation of Notch receptors, which may inhibit the proliferation of tumor cells with an overly-active Notch pathway. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains that lead to their activation. Overexpression of the Notch signaling pathway has been correlated with increased tumor cell growth.

Clinical Trials

View Clinical Trials for al101

Al101 has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating al101, 1 is phase 1 (1 open) and 2 are phase 2 (2 open).

NOTCH1 A1701P, NOTCH1 F1592S, and NOTCH1 I1616N are the most frequent biomarker inclusion criteria for al101 clinical trials.

Adenoid cystic carcinoma and breast carcinoma are the most common diseases being investigated in al101 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Al101
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating al101 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
bms-906024, al 101, al-101, gs/pan-notch inhibitor al101
Drug Target(s) [2]:
NOTCH1, NOTCH2, NOTCH3, NOTCH4
NCIT ID [1]:
C116872

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.